Eledon Pharmaceuticals, Inc. (ELDN:NASDAQ) closed at $2.30 on October 23, 2026, unchanged on the day. The stock trades 50.0% below its 52-week high of $4.60 and 70.4% above its 52-week low of $1.35. Over the past year, it lost 33.9%. Eledon Pharmaceuticals, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ELDN closed higher on 119 days (47%). Its best day was March 31, 2026 (+13.65%) and its worst was November 7, 2025 (-49.76%). The stock moved 10% or more in a single session 10 times.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.
Find more stocks like ELDN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.